Heidelberg, 26 June 2008 – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports its financial results for the period ended 31 March 2008. Fiscal year 2007/2008 was one in which SYGNIS achieved important milestones on its way to building a product-focused pharmaceutical company in the treatment of Central Nervous System (CNS) disorders. The Company has made significant steps in the expansion of its CNS-product pipeline particularly through advancing the development of its lead compound, AX200, and by strengthening both its R&D capabilities and business development activities.
